Bonerge Lifescience Launches Clinical Study on EquoYouth® S-Equol for Menopause Symptom Relief
Open-label trial will evaluate a 12-week, 10 mg daily regimen of the company's high-purity S-equol ingredient in women with moderate menopausal symptoms.
Bonerge Launches Second-Gen Amuctive™ Akkermansia, Shifting Focus from Bacterial Count to Active Protein Potency
Ahead of its showcase at the upcoming SupplySide Global 2025 ingredient exhibition, Bonerge is set to introduce a significant advancement in probiotic supplementation: the second-generation Amuctive™ Akkermansia muciniphila. This launch marks a strategic pivot for the industry, moving beyond merely counting bacterial colonies to ensuring the potency of a key active protein, Amuc_1100.
BeFisetin® Announced the Global No.1 All-Natural Fisetin With SA-GRAS Status
Bonerge Lifescience, a trusted innovator in longevity ingredients, proudly announces a historic milestone: on April 2, 2025, its premium fisetin ingredient, BeFisetin®, has achieved Self-affirmed Generally Recognized as Safe (SA-GRAS) status in the United States. This landmark accomplishment positions Bonerge as the first company globally to secure GRAS certification for fisetin powder, setting a new global benchmark for safety and reliability in the next-generation anti-aging market.
Bonerge Lifescience opened its new manufacturing facility to further support the innovation of its branded ingredients
Bonerge Lifescience, an innovative nutraceutical manufacturer, started to put its newly built factory into operation. The new factory is focusing on manufacturing innovative plant extracts including BefisetinTM, Bonerge’s branded fisetin ingredient. This strategic production expansion accelerates the development of Bonerge’s existing and upcoming branded ingredients.
